Premium
Extracorporeal photopheresis for the treatment of early‐stage mycosis fungoides
Author(s) -
Lewis Daniel J.,
Duvic Madeleine
Publication year - 2017
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12485
Subject(s) - extracorporeal photopheresis , medicine , mycosis fungoides , photopheresis , cutaneous t cell lymphoma , dermatology , tolerability , stage (stratigraphy) , refractory (planetary science) , lymphoma , disease , surgery , adverse effect , graft versus host disease , paleontology , physics , astrobiology , biology
Extracorporeal photopheresis (ECP) has been used for nearly 30 years in the treatment of cutaneous T‐cell lymphoma. However, current clinical practice largely reserves ECP for patients with late‐stage mycosis fungoides (MF) or Sézary syndrome or for those who are refractory to other therapies. We briefly describe a 48‐year‐old male who experienced long‐term complete remission of his patch MF disease with ECP, and we suggest a role for ECP in the treatment of early‐stage MF given evidence of its efficacy, safety, and tolerability.